Knockdown of Long Noncoding RNA PCAT6 Inhibits Proliferation and Invasion in Lung Cancer Cells

Wan, Li; Zhang, Lin; Fan, Kai; Cheng, Zaixing; Sun, Quanchao; Wang, Jianjun

doi:10.3727/096504016x14618564639178

Cited by 45 publications

(73 citation statements)

References 46 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Wan et al's study, PCAT6 was considered as a potential diagnostic and prognostic biomarker in non‐small cell lung cancer . PCAT6 may indirectly regulate c‐Myc and p53 expression in lung cancer which may contribute to the modulation of lung cancer cells proliferation and invasion . In the present study, we also observed higher PCAT6 expression in CRC tissues.…”

Section: Discussionmentioning

confidence: 97%

Long non‐coding RNA PCAT6 targets miR‐204 to modulate the chemoresistance of colorectal cancer cells to 5‐fluorouracil‐based treatment through HMGA2 signaling

Zou

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

Colorectal cancer (CRC) is still the third most common cancer in the world with a limited prognosis due to the chemoresistance of CRC cells to 5‐fluorouracil (5‐FU)‐based chemotherapy. In our previous study, we revealed that miR‐204 overexpression could sensitize CRC cell to 5‐FU treatment through targeting HMGA2/PI3K signaling pathway; however, miR‐204 expression in CRC tissues is abnormally downregulated. Long non‐coding RNAs (lncRNAs) dysregulation has been reported in human diseases, including cancer. Also, lncRNA can regulate cancer cell proliferation, invasion, migration, as well as chemoresistance. LncRNA prostate cancer‐associated transcript 6 (PCAT6) acts as an oncogene in many cancers; herein, PCAT6 expression was abnormally upregulated in CRC tissues and cell lines, suggesting its potential role in CRC. Further, we assessed the specific function and mechanism of PCAT6 in CRC. Furthermore, we revealed that PCAT6 knockdown attenuated CRC chemoresistance to 5‐FU through miR‐204/HMGA2/PI3K; miR‐204 inhibition could partially reverse the effect of PCAT6 knockdown. Taken together, we demonstrate that the abnormal PCAT6 overexpression inhibits miR‐204 expression in CRC, thereby promoting HMGA2/PI3K signaling activity, ultimately enhancing the chemoresistance of CRC cells to 5‐FU; PCAT6 represents a promising target for dealing with CRC chemoresistance.

show abstract

Section: Discussionmentioning

confidence: 97%

Long non‐coding RNA PCAT6 targets miR‐204 to modulate the chemoresistance of colorectal cancer cells to 5‐fluorouracil‐based treatment through HMGA2 signaling

Zou

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Increased SNHG3 expression is associated with malignant status and worse overall survival, recurrence-free survival and disease-free survival in hepatocellular carcinoma patients [50]. PCAT6 may play an oncogenic role in lung cancer progression, and it negatively correlates with the overall survival of lung cancer patients [51]. MIAT may promote the development of lung adenocarcinoma via the MIAT-miR-106-MAPK signalling pathway loop [52].…”

Section: Discussionmentioning

confidence: 99%

Oncogenic long noncoding RNA landscape in breast cancer

et al. 2017

View full text Add to dashboard Cite

BackgroundFew long noncoding RNAs (lncRNAs) that act as oncogenic genes in breast cancer have been identified.MethodsOncogenic lncRNAs associated with tumourigenesis and worse survival outcomes were examined and validated in Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA), respectively. Then, the potential biological functions and expression regulation of these lncRNAs were studied via bioinformatics and genome data analysis. Moreover, progressive breast cancer subtype-specific lncRNAs were investigated via high-throughput sequencing in our cohort and TCGA validation. To elucidate the mechanisms of the regulation of these lncRNAs, genomic alterations from the TCGA, Broad, Sanger and BCCRC data, as well as epigenetic modifications from GEO data, were then applied and examined to meet this objective. Finally, cell proliferation assays, flow cytometry analyses and TUNEL assays were applied to validate the oncogenic roles of these lncRNAs in vitro.ResultsA cluster of oncogenic lncRNAs that was upregulated in breast cancer tissue and was associated with worse survival outcomes was identified. These oncogenic lncRNAs are involved in regulating immune system activation and the TGF-beta and Jak-STAT signalling pathways. Moreover, TINCR, LINC00511, and PPP1R26-AS1 were identified as subtype-specific lncRNAs associated with HER-2, triple-negative and luminal B subtypes of breast cancer, respectively. The up-regulation of these oncogenic lncRNAs is mainly caused by gene amplification in the genome in breast cancer and other solid tumours. Finally, the knockdown of TINCR, DSCAM-AS1 or HOTAIR inhibited breast cancer cell proliferation, increased apoptosis and inhibited cell cycle progression in vitro.ConclusionsThese findings enhance the landscape of known oncogenic lncRNAs in breast cancer and provide insights into their roles. This understanding may potentially aid in the comprehensive management of breast cancer.Electronic supplementary materialThe online version of this article (doi:10.1186/s12943-017-0696-6) contains supplementary material, which is available to authorized users.

show abstract

“…Long non‐coding RNAs (lncRNAs), transcripts longer than 200 nucleotides without protein translation, have been observed to function in carcinogenesis . Some can work as clinically relevant biomarkers since being linked to prognosis .…”

Section: Introductionmentioning

confidence: 99%

Overexpression of AR‐regulated lncRNA TMPO‐AS1 correlates with tumor progression and poor prognosis in prostate cancer

Huang

Wang

et al. 2018

The Prostate

View full text Add to dashboard Cite

show abstract

Knockdown of Long Noncoding RNA PCAT6 Inhibits Proliferation and Invasion in Lung Cancer Cells

Cited by 45 publications

References 46 publications

Long non‐coding RNA PCAT6 targets miR‐204 to modulate the chemoresistance of colorectal cancer cells to 5‐fluorouracil‐based treatment through HMGA2 signaling

Long non‐coding RNA PCAT6 targets miR‐204 to modulate the chemoresistance of colorectal cancer cells to 5‐fluorouracil‐based treatment through HMGA2 signaling

Oncogenic long noncoding RNA landscape in breast cancer

Overexpression of AR‐regulated lncRNA TMPO‐AS1 correlates with tumor progression and poor prognosis in prostate cancer

Contact Info

Product

Resources

About